Cytisinicline - Achieve Life Sciences

Alternative Names: Cytisine; Cytisine-Achieve-Life-Sciences; Desmoxan; Tabex

Latest Information Update: 02 Aug 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sopharma
Developer Achieve Life Sciences
Class 2 ring heterocyclic compounds; Alkaloids; Pyridones; Small molecules; Smoking cessation therapies
Mechanism of Action Alpha4 beta2 nicotinic receptor agonists; Chelating agents

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

31 Jul 2024 Achieve life sciences plans to hold an End-of-Phase 2 meeting with the US FDA under the Breakthrough Therapy Designation before the end of the year
31 Jul 2024 Cytisinicline - Achieve Life Sciences receives Breakthrough Therapy status for Smoking withdrawal in USA
24 May 2024 Achieve Life Sciences initiates enrolment in the phase III ORCA-OL trial for Smoking withdrawal in USA (NCT06435221)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com